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Hepatic ischemia and reperfusion (IR) injury is a major clinical
problem often leading to acute kidney injury characterized
by early endothelial cell apoptosis, subsequent neutrophil
infiltration, proximal tubule necrosis/inflammation, impaired
vascular permeability, and disintegration of the proximal
tubule filamentous actin cytoskeleton. Activated protein C is
a major physiological anticoagulant with anti-inflammatory
and anti-apoptotic activities in endothelial cells. Here we
tested if activated protein C would attenuate hepatic and
renal injury caused by hepatic ischemia and reperfusion. Both
liver and kidney injury were significantly reduced when
activated protein C was given immediately before and 2h
after liver reperfusion, in that there was reduced renal
endothelial and hepatocyte apoptosis, as well as reduced
hepatic and renal tubular necrosis. Further, the
administration of activated protein C also reduced the
expression of several pro-inflammatory genes, liver and
kidney filamentous-actin degradation, and neutrophil
infiltration, and resulted in better preservation of vascular
permeability of both the liver and kidney than is normally
seen after liver ischemia and reperfusion. These protective
effects of activated protein C were due to protease-activated
receptor-1 modulation since administration of a selective
receptor antagonist dose-dependently inhibited its
ameliorative effects in both organs after liver ischemia and
reperfusion. Our results suggest the powerful multi-organ
protective effects of activated protein C may improve
outcome in those patients at significant risk of developing
acute kidney injury following liver ischemia and reperfusion
during transplantation.
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Hepatic ischemia and reperfusion (IR) is a common problem
encountered in many clinical conditions including liver
transplantation, major hepatic resection, and prolonged
portal vein occlusion.1,2 The pathophysiology of hepatic IR
injury is complex and involves complex orchestration of
necrosis, apoptosis, and inflammation of hepatic (hepato-
cytes, Kupffer cells) and extra-hepatic (leukocytes, circulating
cytokines) components. Hepatic IR frequently leads to
remote organ injury including the kidney, lung, and heart.3,4
In particular, acute kidney injury (AKI) after major liver IR is
extremely common (40–85% incidence) and the development
of AKI after liver injury implies high mortality and morbidity
during the perioperative period. We recently developed a
murine model of liver IR-induced AKI characterized by early
renal endothelial apoptosis and dysfunction, proximal tubule
inflammation, and necrosis.5 Liver IR-induced AKI also
produced severe impairment in vascular permeability of the
liver and the kidney together with filamentous (F)-actin
degradation.5 Therefore, AKI developed because liver IR is a
disease of early endothelial apoptosis and dysfunction, renal
inflammation with subsequent F-actin degradation, and
tubular necrosis.
Activated protein C (APC) is a serine protease with
powerful anticoagulant activities in endothelial cells.6 In
addition to its effects on coagulation, APC also exerts anti-
inflammatory, antiapoptotic and cytoprotective effects.7
Moreover, APC promotes microvascular integrity, provides
powerful endothelial barrier protection, and disrupts the
amplification of coagulation defects secondary to an
uncontrolled inflammatory response after IR injury or severe
sepsis.8 Soluble thrombomodulin, an important co-factor of
thrombin-mediated cleavage and activation of protein C,
provided powerful protection against hypoperfusion-induced
AKI in rats when given before or after ischemic injury.9 Based
on these protective effects, APC has been considered as a
potent prophylactic and/or therapeutic agent to attenuate
microvascular injury, inflammatory response, and septic
shock.10 Recently, there are reports showing that APC
prevents post-ischemic damage in the brain,11 heart,12 and
intestine13 after IR. All of the protective effects of
APC (endothelial protection, reduction in apoptosis,
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inflammation, and preservation of microvascular permeabil-
ity) would negate the pathological changes observed in liver
IR injury and subsequent AKI.
Therefore, in this study, we examined whether APC
treatment could protect against both hepatic and renal injury
induced by hepatic IR. We show that APC treatment
improved renal and hepatic function after liver IR. We also
demonstrate that mice treated with APC benefited signifi-
cantly with a reduced inflammatory response, better
preservation of microvascular permeability, less disruption
of the F-actin cytoskeleton, and reduced apoptotic changes of
the liver and kidney after severe liver IR injury. We also
demonstrate that the protective effects of APC is due to
protease-activated receptor-1 (PAR-1) modulation as a
selective PAR-1 receptor antagonist (SCH 79797) dose-
dependently inhibited APC’s protective effects against liver
and kidney injury after liver IR.
RESULTS
APC treatment protects against hepatic and renal injury
after liver IR
The plasma level of alanine aminotransferase (ALT) and
creatinine (Cr) in the sham-operated mice was 62±8U/l
(N¼ 6) and 0. 41±0.04mg per 100ml (N¼ 7), respectively.
APC treatment produced dose (40–250 mg/kg i.v. before
reperfusion and 80–500 mg/kg s.c. 2 h after reperfusion)
dependent protection against liver as well as renal injury
24 h after liver IR (Figure 1). In the saline-IR group,
the plasma level of ALT and Cr increased at 5
(ALT¼ 20097±1434 U/l, N¼ 8, Po0.01 vs Sham, and
Cr¼ 0.60±0.09mg per 100ml, N¼ 8) and 24 h
(ALT¼ 15211±1190 U/l, N¼ 8, Po0.01 vs Sham, and
Cr¼ 1.11±0.10mg per 100ml, N¼ 8, Po0.01 vs Sham)
after reperfusion. The increases in ALT were significantly
suppressed by APC treatment (250 mg/kg i.v. before reperfu-
sion and 500 mg/kg s.c. 2 h after reperfusion) at 5 h
(ALT¼ 12118±1369 U/l, N¼ 6, Po0.01) and 24 h
(ALT¼ 6276±1107U/l, N¼ 8, Po0.001) after reperfusion.
The increases in Cr were significantly suppressed by APC
treatment (250 mg/kg i.v. before reperfusion and 500 mg/kg
s.c. 2 h after reperfusion) at 24 (Cr¼ 0.29±0.06mg per
100ml, N¼ 6, Po0.001) but not at 5 h (Cr¼ 0.49±0.09mg
per 100ml, N¼ 6, NS) after reperfusion. The urinary
ALT was nearly undetectable in sham-operated mice
(ALT¼ 0.6±0.3 U/l, N¼ 7) and did not significantly
increase in mice subjected to liver IR (ALT¼ 14.8±11 U/l,
N¼ 8, P¼ 0.25). The survival rates for saline- (70%, N¼ 20)
or APC-treated (90%, N¼ 10) mice were not statistically
different at 24 h after liver IR (w2 test).
We also tested whether the blockade of protease-activated
receptor-1 (PAR-1) would prevent the renal and hepatic
protective effects of APC after liver IR. We used SCH 79797
(N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-
pyrrolo[3,2-f]quinazoline-1,3 diamine, Tocris Bioscience,
Ellisville, Missouri, USA) to block PAR-1 and then adminis-
tered APC in mice subjected to liver IR. SCH 79797 in a dose-
dependent manner (0.02–0.5mg/kg) prevented the hepatic
and renal protective effects of APC treatment (250 mg/kg i.v.
before reperfusion and 500 mg/kg s.c. 2 h after reperfusion) at
5 h (not shown) and at 24 h after liver IR in mice (Figure 1c
and d). We also noted that an intermediate dose of this PAR-
1 antagonist (0.1mg/kg SCH 79797) produced moderate
hepatic (but not renal) protection after liver IR (Figure 1c).
APC treatment reduces hepatic necrosis after IR
Representative histological slides (magnification,  40) from
liver tissues from saline-treated and APC-treated mice
subjected to 60min ischemia and 24 h reperfusion or to
sham operation are shown in Figure 2. Sixty minutes of
partial hepatic IR produced large necrotic areas of livers after
reperfusion (Figure 2a). Correlating with significantly
improved function, reduced necrosis was observed in mice
treated with APC and subjected to hepatic IR (Figure 2a).
The average percent necrotic areas for saline-treated mice
were 61±6% (N¼ 7) and APC-treatment reduced this
percent necrosis to 38±8% (N¼ 7, Po0.03). We failed to
detect necrosis in liver sections from sham-operated mice.
Livers were also analyzed for the degree of hepatocellular
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Figure 1 |APC protects liver and kidney against hepatic IRI.
(a and b). Dose-dependent protective effects of APC against
hepatic (a, ALT) and renal (b, creatinine) injury in C57BL/6 mice
subjected to sham operation (sham), saline treatment, and liver
ischemia and reperfusion (IR) or APC treatment during and after
liver IR (APCþ IR). Three doses of APC were given to mice: 40mg/
kg i.v. before reperfusion and 80 mg/kg s.c. 2 h after reperfusion
(40þ 80), 100mg/kg i.v. before reperfusion and 200mg/kg s.c. 2 h
after reperfusion (100þ 200), or 250 mg/kg i.v. before reperfusion
and 500mg/kg s.c. 2 h after reperfusion (250þ 500). **Po0.01 vs
sham group. #Po0.05 and ##Po0.01 vs IR group. (c and d). SCH
79797 (N3-Cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-
pyrrolo[3,2-f]quinazoline-1,3-diamine-dihydrochloride) in a dose-
dependent manner (0.02–0.5mg/kg) prevented the hepatic (c)
and renal protective effects (d) of APC treatment (250mg/kg i.v.
before reperfusion and 500mg/kg s.c. 2 h after reperfusion) at 5 h
(not shown) and at 24 h after liver IR in mice. *Po0.01 vs vehicle-
treated IR group. #Po0.05 vs APC IR group. Data are presented as
mean±s.e.m.
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damage using Suzuki’s criteria.14 The ischemic lobes in the
control group showed severe hepatocyte necrosis and
sinusoidal congestion (Suzuki score¼ 10.7±0.6, N¼ 6).
Mice treated with APC revealed significantly less necrosis/
sinusoidal congestion and better preservation of lobular
architecture (Suzuki score¼ 7.8±0.7, N¼ 6, Po0.01).
APC treatment reduces renal cortical vacuolization, proximal
tubular simplification, and hypereosinophilia after liver IR
When we examined the kidneys from the mice injected with
saline vehicle and subjected to liver IR, we observed
multifocal acute tubular injury including S3 segment
proximal tubule necrosis, cortical tubular simplification,
cytoplasmic vacuolization, and dilated lumina as well as focal
granular bile/heme casts (Figure 2b). Representative H&E
slides from kidneys from saline-treated and APC-treated
mice subjected to 60min ischemia and 24 h reperfusion or to
sham operation are shown in Figure 2b (magnification,
 200). Correlating with significantly improved renal func-
tion, mice treated with APC showed less renal tubular
hypereosinophilia and cortical vacuolization (Figure 2b).
APC treatment reduces hepatic and renal neutrophil
infiltration 24h after liver IR
Figure 3 shows representative images of neutrophil immu-
nohistochemitry of liver (A, magnification  100) and
kidney (B, magnification  400) sections from mice
subjected to sham operation or to 60min of liver ischemia
and 24 h reperfusion. In sham-operated mice, we were unable
to detect any neutrophils in the liver or kidney. Sixty minutes
of hepatic ischemia and 24 h reperfusion resulted in
recruitment of neutrophils into the liver (Figure 3a).
Neutrophil infiltration coincided with areas of liver necrosis.
Subsequently, although mice treated with APC and subjected
to liver IR had reduced areas of liver necrosis, the number
of neutrophils present in the necrotic areas visualized
(19.8±6.2 neutrophils/field,  200 magnification, N¼ 6)
was similar to the animals subjected to liver IR after vehicle
(saline) injection (24.2±1.7 neutrophils/field,  200 magni-
fication, N¼ 6, Figure 3a).
Sixty minutes of hepatic ischemia also resulted in
recruitment of neutrophils into the kidney (Figure 3b).
Neutrophil infiltration 24 h after hepatic ischemia was
significantly less in APC-treated mice compared with the
saline-treated mice subjected to liver IR. Twenty-four hours
after liver IR, we detected 9.3±3.4 neutrophils/field ( 200
magnification, N¼ 5) in saline-treated mice subjected to liver
IR. APC-treated mice had significantly reduced neutrophil
infiltration 24 h after liver IR (1.3±0.9 neutrophils/field,
 200 magnification, N¼ 5, Po0.05).
APC-treatment decreases hepatic and renal vascular
permeability after liver IR
We measured liver vascular permeability after liver IR with
Evans blue dye (EBD) injection. EBD binds to plasma
proteins and its appearance in extravascular tissues reflects an
increase in vascular permeability. Analysis of EBD extravasa-
tions in saline- and APC-treated mice subjected to sham-
operation and liver IR are shown in Figure 4. Liver IR
increased the EBD content in the liver for both groups,
however, the increase in EBD content was significantly higher
for the saline-treated mice (376.5±37.4 mg EBD/g dry liver,
N¼ 6) compared with the APC-treated mice (167.5±22.8 mg
EBD/g dry liver, N¼ 6, Po0.001). Liver IR also increased
the EBD content in the kidney for both groups, however, the
increase in EBD content was significantly higher for the
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Figure 2 |APC improves histology after liver IRI in the liver and kidney. Representative photomicrographs of hematoxylin and eosin
staining of the liver (a, 40) and kidney (b, 200) sections. C57BL/6 mice were subjected to sham operation (sham), saline treatment, and
liver ischemia and reperfusion (IR) or APC treatment during and after liver IR (APCþ IR), and the liver and kidney sections were obtained 24 h
after reperfusion. *A representative dilated tubule from simplification, arrow indicates cytoplasmic vacuolization, arrowhead indicates
hypereosinophilic tubule cell death, and double arrowhead indicates peritubular vascular stasis. Photographs are representative of six
independent experiments.
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saline-treated mice (83.5±4.3 mg EBD/g dry kidney, N¼ 6)
compared with the APC-treated mice (48.8±8.2 mg EBD/g
dry kidney, N¼ 6, Po0.001).
APC treatment reduces plasma TNF-a after liver IR
In sham-operated animals, the plasma TNF-a level was not
detectable. In contrast, the plasma TNF-a level increased
markedly to 852.3±80.8 pg/ml (N¼ 4) 24 h after liver IR.
However, this increase was attenuated by APC treatment
(23.5±23.5 pg/ml, N¼ 4, Po0.001, Figure 5).
APC treatment reduces TNF-a mRNA in the liver and MCP-1
and MIP-2 mRNA in the kidney after liver IR
We measured the expression of pro-inflammatory cytokine
mRNAs in the liver and the kidney at 5 h and 24 h after liver
IR with semi-quantitative RT-PCR. Hepatic IR was associated
with significantly increased pro-inflammatory mRNA ex-
pression at 5 h (ICAM-1, TNF-a, KC, MCP-1, and MIP-2) in
the liver (Figure 6) as well as in the kidney (Figure 7) from
saline-treated mice compared with the sham-operated mice.
These increases in pro-inflammatory mRNA expression were
also observed at 24 h after reperfusion (data not shown).
However, APC-treated mice showed significantly reduced
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Figure 3 |APC reduces neutrophil infiltration after liver IRI in the liver and kidney. Representative of photomicrographs of
immunohistochemistry for neutrophils in liver (a,200) and kidney (b,400) sections. C57BL/6 mice were subjected to sham operation
(sham), saline treatment, and liver ischemia and reperfusion (IR) or APC treatment during and after liver IR (APCþ IR) and the liver and
kidney sections were obtained 24 h after reperfusion. Photographs are representative of six independent experiments.
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Figure 4 |APC improves vascular permeability after liver IRI in
the liver and kidney. Evans blue dye (EBD) extravasations as
indices of vascular permeability of liver (a) and kidney (b) tissues in
C57BL/6 mice subjected to sham operation (sham), saline
treatment, and liver ischemia and reperfusion (IR) or APC treatment
during and after liver IR (APCþ IR). The liver and kidney tissues
were obtained 24h after reperfusion. Data are presented as
means±s.e.m. *Po0.001 vs sham group. #Po0.001 vs IR group.
Sham IR APC + IR
0
250
500
750
1,000
*
#
Pl
as
m
a 
TN
F-
α
 
(pg
/m
l)
Figure 5 |Plasma TNF-a levels in C57BL/6 mice subjected to
sham operation (sham), saline treatment, and liver ischemia
and reperfusion (IR) or APC treatment during and after liver
IR (APCþ IR). The blood samples were collected 24 h after
reperfusion. Data are presented as mean±s.e.m. *Po0.001 vs
sham group. #Po0.001 vs IR group.
742 Kidney International (2009) 76, 739–750
or ig ina l a r t i c l e SW Park et al.: APC mediated liver and kidney protection
TNF-a mRNA in the liver and MCP-1 and MIP-2 mRNA in
the kidney compared with the saline-treated mice at 5 h
(Figures 6 and 7) and at 24 h (data not shown) after liver IR.
There were no significant differences in other pro-inflam-
matory mRNAs. Inhibition of PAR-1 with SCH 79797
(0.5mg/kg i.p.) 1 h before APC treatment (250 mg/kg i.v.
before reperfusion and 500 mg/kg s.c. 2 h after reperfusion)
prevented the reduction of TNF-a mRNA in the liver and
MCP-1 and MIP-2 mRNA in the kidney at 5 h and at 24 h
after liver IR (data not shown).
APC treatment reduces hepatic and renal apoptosis after
liver IR
We used three separate indices to detect apoptosis: TUNEL
staining, DNA laddering, and caspase 3 fragmentation. APC
treatment significantly reduced the apoptosis of the liver and
kidney compared with the saline-treated mice with reduced
TUNEL staining (Figure 8), DNA laddering (Figure 9), and
caspase 3 fragmentation (Figure 10). The TUNEL staining
showed that endothelial apoptosis was predominant in the
kidney (Figure 8b inset).
APC treatment reduces the degradation of hepatic and renal
F-actin after liver IR
Liver staining in sham-operated mice shows localization of
F-actin at the hepatocyte basolateral membranes and the bile
canalicular membranes (Figure 11a). As expected, 60min of
liver ischemia and 24 h of reperfusion resulted in severe
disruption of liver parenchymal F-actin compared with the
sham-operated mice (Figure 11a, representative of six
experiments) in saline-treated mice as the staining of
basolateral hepatocyte membranes as well as bile canalicular
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Figure 6 | Effect of APC on pro-inflammatory gene expression
in the liver after hepatic IR. (a) Representative gel images of
RT-PCR results for GAPDH, TNF-a, ICAM-1, KC, MCP-1, and MIP-2
mRNAs of liver tissue. C57BL/6 mice were subjected to sham
operation (sham), saline treatment, and liver ischemia and
reperfusion (IR) or APC treatment during and after liver IR
(APCþ IR). The liver tissues were obtained 5 h after reperfusion.
(b) Densitometric quantification of relative TNF-a band intensities
normalized to GAPDH from RT-PCRs. Data are presented as
means±s.e.m. *Po0.05 vs sham group. #Po0.05 vs IR group.
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Figure 7 | Effect of APC on pro-inflammatory gene expression
in the kidney after hepatic IR. (a) Representative gel images of
semi-quantitative RT-PCR results for GAPDH, TNF-a, ICAM-1, KC,
MCP-1, and MIP-2 mRNAs of kidney tissue. C57BL/6 mice were
subjected to sham-operation (sham), saline treatment, and liver
ischemia and reperfusion (IR) or APC treatment during and after
liver IR (APCþ IR). The kidneys were obtained 5 h after
reperfusion. (b) Densitometric quantification of relative MCP-1
and MIP-2 band intensities normalized to GAPDH from RT-PCRs.
Data are presented as means±s.e.m. *Po0.05 vs sham group.
#Po0.05 vs IR group.
Kidney International (2009) 76, 739–750 743
SW Park et al.: APC mediated liver and kidney protection o r ig ina l a r t i c l e
membranes is strongly decreased and disorganized. However,
APC-treated mice subjected to liver IR show significantly
better preserved F-actin structure after liver IR as the staining
is quite similar to that of sham-operated mice. Liver IR also
resulted in a severe loss of F-actin in renal proximal tubules
in 24 h. In Figure 11a, 24 h post-hepatic IR-induced
disruptions of the F-actin cytoskeleton in renal proximal
tubular epithelial cells are also shown. Mice subjected to
sham surgery showed intense stain in the tubular epithelial
and in the basal plasma membrane. In contrast, kidneys from
saline-treated mice subjected to liver IR showed loss of
F-actin staining in the tubular epithelial cells. However, the
APC-treated mice show significantly better preserved F-actin
structure after liver IR as the staining is quite similar to that
of sham-operated mice. Mean fluorescent F-actin intensity
showed reduced hepatocyte and renal proximal tubule
F-actin degradation in APC-treated mice after liver IR
(Figure 11b).
DISCUSSION
The major findings of this study are that mice treated with
human APC show reduced hepatic and renal injury after liver
IR, which was reversed by pretreatment with the PAR-1
antagonist SCH 79797. APC-treated mice subjected to liver
IR show (1) reduced hepatic and renal necrosis as well as
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Figure 8 |Representative fluorescent photomicrographs of liver and kidney sections illustrate apoptotic nuclei (TUNEL fluorescent
stain, magnification 100). C57BL/6 mice were subjected to sham operation (sham), saline treatment, and liver ischemia and reperfusion
(IR) or APC treatment during and after liver IR (APCþ IR). The liver (a) and kidney (b) sections were obtained 24 h after reperfusion.
Photographs are representative of six independent experiments. Insets show a higher magnification of the images showing TUNEL positive
cells. In the kidney, endothelial cells and not proximal tubule cells underwent apoptosis.
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Figure 9 |Representative gel images demonstrating DNA
laddering as an index of DNA fragmentations in the liver and
kidney tissues. C57BL/6 mice were subjected to sham operation
(sham), saline treatment, and liver ischemia and reperfusion (IR) or
APC treatment during and after liver IR (APCþ IR). The liver and
kidney tissues were obtained 24 h after reperfusion. Photographs
are representative of five independent experiments.
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apoptosis, (2) decreased neutrophil infiltration of the kidney,
(3) improved vascular permeability indicating better pre-
served endothelial integrity of the liver and the kidney, (4)
attenuated expression of certain pro-inflammatory mRNAs
in the liver and the kidney and a reduction in plasma TNF-a
levels and (5) better preserved F-actin cytoskeleton structure
after liver IR.
Hepatic IR-induced acute liver dysfunction is a very
common clinical problem and frequently complicates several
surgical procedures including major liver resection, proce-
dures requiring prolonged portal vein occlusion and
orthotopic liver transplantation.15 Unfortunately, neither
effective prevention nor therapy exists for hepatic IR-induced
liver dysfunction and the current management remains
largely supportive.2 Furthermore, hepatic IR is also known
to cause remote organ injury resulting in myocardial
dysfunction, pulmonary failure, and AKI.3,5 In particular,
AKI associated with liver failure is a grave clinical problem
with a high mortality rate.16 Therapy for AKI also remains
largely supportive and limited to hydration, blood pressure
support and short-term hemodialysis until renal function
recovers.
In human liver transplantation surgery involving obliga-
tory prolonged liver ischemia, severe inflammatory responses
during reperfusion may lead to protein C and APC utilization
within the liver leading to systemic depletion.17 Therefore, we
hypothesized that an exogenous supply of APC would protect
against the detrimental effects of liver IR and attenuate
remote kidney injury associated with liver IR. In this study,
hepatic IR-induced severe hepatocellular damage resulting in
a dramatic elevation of plasma ALT level at 5 and 24 h of
reperfusion. Moreover, liver IR also caused subsequent AKI
during the late phase of reperfusion (24 h). APC treatment
significantly attenuated the elevation of plasma ALT and
creatinine levels. Therefore, these results show that APC has a
protective effect against liver as well as kidney injury caused
by hepatic IR.
Protein C produces three distinct but perhaps interrelated
physiological effects.18 It is one of the main physiological
vitamin K-dependent anticoagulants in the blood. Upon
activation by thrombin–thrombomodulin complex at the
endothelial surface, it is converted to an active form of the
serine protease, APC.19 APC produces anticoagulant activity
by inhibiting thrombin generation by selective proteolytic
inactivation of factors Va and VIIIa and stimulates fibrino-
lysis by diminishing thrombin generation with subsequent
reduction in thrombin-dependent PAR-1 cleavage. In addi-
tion, APC is a powerful endogenous cytoprotective agent
with anti-inflammatory and antiapoptotic properties.
Furthermore, APC attenuates the activation of leukocytes
and suppresses cytokine production.20 APC’s cytoprotective
effects are secondary to endothelial protein C receptor
activation with subsequent cleavage of protease-activated
receptor-1.18 Finally, APC may reduce neutrophil migration
via PAR-1 independent mechanisms, thereby also reducing
inflammation. All of these physiological effects of APC
(anticoagulant, antiapoptotic, anti-inflammatory, endothelial
protection) are perfectly suited to attenuate the detrimental
effects of liver IR and subsequent remote kidney injury.
Indeed, APC infusion or injection has been shown to protect
against liver injury after hepatectomy21 and in animals
subjected to endotoxemia22 and peritonitis.23 However, the
protective effect of APC on renal function after hepatic IR
injury has never been described. Utilization of APC to treat
AKI associated with liver IR is particularly exciting as we saw
changes in the kidney after liver IR that may be mitigated by
APC (endothelial apoptosis, tubular inflammation and
apoptosis, and F-actin degradation).5 Therefore, we exam-
ined in this study whether APC treatment has a protective
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Figure 10 | Effect of APC on caspase 3 fragmentation after
hepatic IR. Top: representative caspase 3 fragmentation in liver
(a) and kidney (b) tissues. C57BL/6 mice were subjected to sham
operation (sham), saline treatment, and liver ischemia and
reperfusion (IR) or APC treatment during and after liver IR
(APCþ IR). The liver and kidney tissues were obtained 24 h after
reperfusion. Photographs are representative of four independent
experiments. Bottom: densitometric quantifications of cleaved
caspase 3 (pro-caspase 3) mice subjected to sham operation or
liver IR (N¼ 4 for each group). *Po0.05 vs sham group. #Po0.05
vs IR group.
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effect against hepatic as well as renal injury that occur after
liver IR. We demonstrated in this study that a selective PAR-1
receptor antagonist (SCH 79797) dose-dependently inhibited
APC’s protective effects against liver and kidney injury after
liver IR. SCH 79797 also blocked the reduction in TNF-a
mRNA in the liver and MCP-1 and MIP-2 mRNA in the
kidney induced by APC treatment after liver IR. Therefore,
we conclude that the cytoprotective effects of APC against
liver IR is due to PAR-1 modulation. Although dose-
dependent inhibition of APC was provided by the PAR-1
antagonist, we also noticed that an intermediate dose of this
PAR-1 antagonist (0.1mg/kg SCH 79797) produced moder-
ate hepatic (but not renal) protection after liver IR. After
myocardial IR in rats, this PAR-1 antagonist also provided
protection.24
In this study, we demonstrate that APC treatment
significantly reduced the necrosis of liver parenchyma as well
as renal proximal tubules after liver IR. Necrotic liver cell
death occurs directly by total breakdown of cellular
homeostatic machinery secondary to massive depletion of
ATP during and after the ischemic period. Necrosis can also
occur during reperfusion where uncontrolled delivery of
cytotoxic cytokines or free radicals cause further cellular
derangements.25 We also demonstrate that APC treatment
also suppress apoptotic cell death of the liver and the kidney
after liver IR (reduced TUNEL staining, DNA laddering,
caspase 3 fragmentation). Apoptosis is an important
contributor in the development of liver failure after IR.26
Apoptotic cell death represents the execution of an ATP-
dependent death program often initiated by death ligand/
death receptor interactions, such as Fas ligand with Fas,
which leads to a caspase 3 activation and cleavage of DNA
and the DNA-reparative enzyme poly (ADP-ribose) poly-
merase (PARP).27 APC was able to reduce both hepatic as
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Figure 11 | Effect of APC on F-actin degradation after hepatic IR. (a) Representative fluorescent photomicrographs of phalloidin staining
of the liver and kidney tissues (magnification 400). C57BL/6 mice were subjected to sham operation (sham), saline treatment, and liver
ischemia and reperfusion (IR) or APC treatment during and after liver IR (APCþ IR). The liver and kidney sections were obtained 24 h after
reperfusion. In the liver, F-actin is localized in basolateral membranes (arrow) and bile canalicular membranes. Transverse sections of bile
canaliculi are seen as typical dots (arrowhead). In the kidney, F-actin stains of proximal tubular epithelial cells are prominent in the brush
border from sham-operated mice (*), which is severely degraded in the kidneys of mice subjected to liver IR (#). Photographs are
representative of six independent experiments. (b) Quantification of mean fluorescent hepatocyte (N¼ 6) and renal proximal tubule (N¼ 6)
F-actin intensity. *Po0.05 vs sham group. #Po0.05 vs IR group.
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well as renal apoptosis. Although we saw global apoptotic
changes in the liver after IR, the pattern of apoptosis in the
kidney after liver IR was unique (and different compared
with the pattern observed after renal IR) in that endothelial
apoptosis predominated (Figure 8b and Lee et al.5). We
propose that protection of renal endothelial apoptosis is a
crucial mechanism of renal protection with APC after hepatic
IR. Reduction in renal endothelial apoptosis would lead to
better preserved vascular permeability, reduced neutrophil
infiltration with subsequently reduced proximal tubule cell
death. All of these changes were observed in the kidneys of
APC-treated mice subjected to liver IR.
We used a model of AKI in mice induced with liver IR that
is reproducible, rapid to develop (in less than 24 h) and
mimics the histological (renal tubular damage, apoptosis,
necrosis, and juxtaglomerular apparatus hyperplasia) as well
as biochemical (plasma creatinine, inflammatory markers)
changes observed with human AKI associated with liver
failure.5 The pathophysiological and biochemical mechan-
isms of AKI associated with liver IR appear to be multi-
factorial involving portal hypertension-induced splanchnic
vasodilatation with subsequent intrarenal vasoconstric-
tion28–30 coupled with a systemic inflammatory response
after liver IR.30,31 After liver IR injury, circulating pro-
inflammatory cytokines including TNF-a increase signifi-
cantly.32 We determined in this study that plasma TNF-a
levels increased significantly after liver IR and APC treatment
attenuated this increase, which may have contributed to the
reduction in the degree of AKI after liver IR.
The production of several pro-inflammatory cytokines
and adhesion molecules after hepatic IR contributes to the
pathophysiology of liver injury.1,33 We demonstrate that as
expected, all of the pro-inflammatory mRNAs examined in
the liver (TNF-a, KC, MCP-1, MIP-2, and ICAM-1) show
enhanced expression after hepatic IR. However, we only saw
reductions in TNF-a mRNA after liver IR in mice treated
with APC. This attenuation in TNF-a mRNA is consistent
with a significant reduction in plasma TNF-a protein levels
detected with ELISA. We also measured the pro-inflamma-
tory mRNA expression in the kidney after liver IR and similar
to the liver, we saw drastic increases in the expression of
several pro-inflammatory mRNAs. However, we saw sig-
nificant reductions in the expression of only two pro-
inflammatory mRNAs (MIP-2 and MCP-1) in APC-treated
mice. The CC chemokine MCP-1 and CXC chemokine MIP-2
are important mediators in the pathogenesis of AKI.34
Upregulation of MCP-1 and MIP-2 leads to neutrophil
recruitment during AKI induced by renal IR or nephrotoxic
agents.35 APC may have directly but selectively attenuated the
MIP-2 and MCP-1 expression in the kidney, but more likely,
the reduction in hepatic TNF-a expression with APC
treatment resulted in a secondary reduction in MIP-2 and
MCP-1 expression in the kidney. Moreover, TNF-a is known
to promote the migration of inflammatory cells into the renal
parenchyma via the upregulation of MCP-1 and MIP-2 in the
kidney.36
The role of neutrophils in the pathophysiology of organ
injury (including the liver and the kidney) is well
recognized.37 Our study demonstrated that liver IR not only
caused rapid infiltration of neutrophils in the liver but also
caused neutrophil infiltration in the kidney. Neutrophils are
activated during and after liver ischemia and activated
neutrophils attach to and then transverse the hepatic capillary
endothelium into the subendothelial space, where they
release enzymes and cytokines, causing direct hepatocyte
injury and recruit other injurious cells, such as monocytes
and macrophages.38,39 Activated neutrophils release sub-
stances to produce further tissue injury such as products of
arachidonic acid metabolism, oxygen-free radicals and
neutrophil elastase.37 Treating mice with APC resulted in
improved kidney vascular endothelial integrity (indicated by
reduced EBD infiltration) which most likely was responsible
for the limited PMN infiltration into the kidney.
Ischemia-reperfusion injury in vivo results in F-actin
cytoskeleton degradation, which further compromises organ
function.40,41 For example, F-actin disruption is a well known
stimulus of apoptosis in several cell lines.42 We saw severe
disruption of F-actin in the liver as well as in the kidney
proximal tubules after liver IR in saline-treated mice.
Specifically, we saw severe disruptions in both hepatocyte
and bile canalicular F-actin cytoskeleton after liver IR (Figure
11). Remarkably, proximal tubule brush border F-actin was
completely disrupted after liver IR (Figure 11). In this study,
we showed that APC treatment resulted in markedly better
preserved F-actin in the liver as well as the kidney.
Preservation of an intact F-actin cytoskeleton in the liver
and the kidney of mice subjected to liver IR may have
contributed to reduced necrosis and apoptosis observed in
these mice.
APC produces dual effects in vivo; anticoagulant or
cytoprotective. Clinical APC therapy may be limited by its
anticoagulant properties with increased risk of bleeding. In
fact, an increased risk of bleeding has been observed in
clinical trials (PROWESS trial),43 although, in this study the
mice subjected to major laparotomy and liver ischemia well-
tolerated the APC injections. Several APC variants with
varying antithrombotic and cytoprotective activities have
been designed.44,45 In fact, Gupta et al.46 generated APC
variants to study the relative contributions of the two
functions of APC in a rat model of LPS-induced renovascular
dysfunction. In their study, they used two variants of wild-
type APC: K193E (a variant with impaired anticoagulant
activity with intact PAR-1-dependent signaling) and L8W (a
variant with normal anticoagulant activity without the ability
to modulate PAR-1). They determined that the PAR-1
modulation without the anticoagulant function of APC
reversed LPS-induced hypotension. In contrast, both func-
tions of APC had a role in reversing LPS-induced decreases in
renal blood flow and volume to have distinct roles in
attenuating the response to injury in the kidney. In our
model of APC-mediated kidney and liver protection, the
cytoprotective signaling is through agonism of the PAR-1
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receptor as inhibition of PAR-1 with SCH 79797 blocked the
protective effects of APC.
Our model of liver IR-induced AKI demonstrates that the
plasma ALT and Cr has a direct and linear relationship: mice
with higher ALT showed increased renal dysfunction after
liver IR. We also noted that the degree of renal dysfunction
was mild when the plasma ALT levels were below 10,000U/l.5
In the study by Behrends et al.,3 rats subjected to 75min of
partial liver IR developed acute liver dysfunction at 24 h.
However, the degree of renal dysfunction in their rat model
was mild with modest increases in plasma creatinine,
upregulation of ICAM-1 mRNA expression but no changes
in renal MCP-1, MIP2, and iNOS expression. Furthermore,
the kidneys from rats subjected to liver IR showed little
morphological damage and they failed to see increases in
apoptosis (caspase-3) and neutrophil infiltration (myeloper-
oxidase activity). The reason for this discrepancy between our
mouse model and the previous rat model is unclear but is
likely related to differences in the severity of liver injury
which in turn influences the degree of kidney injury. In the
study by Behrends et al.3 plasma ALT rose only toB6800U/l
whereas in our mouse model, the plasma ALT rose much
higher (B15–2,0000U/l). Longer liver ischemic period (for
example, 90min) in a rat is usually lethal (unpublished
observations). Therefore, it appears that the murine model is
better suited as a model of liver failure-induced AKI than the
rat model.
In conclusion, this is the first study to demonstrate the
protective effects of APC on both hepatic and renal
dysfunction induced with hepatic IR injury. Our study shows
that APC attenuates both hepatic and renal injury after liver
IR by reducing necrosis, inflammation, and apoptosis of both
organs. APC treatment led to better preserved F-actin
cytoskeleton and improved vascular integrity of the liver as
well as the kidney after liver IR. Moreover, APC treatment
reduced neutrophil infiltration into the kidney after liver IR.
Therefore, the APC-signaling pathway may be considered as a
promising pharmacological strategy for protecting both liver
and kidney function during and after hepatic IR.
MATERIALS AND METHODS
Reagents
Human APC was purchased from Haematologic Technologies (Essex
Junction, VT, USA). Unless otherwise specified, all reagents were
purchased from Sigma (St. Louis, MO, USA).
Murine model of hepatic IR
All protocols were approved by the Institutional Animal Care and
Use Committee of Columbia University. Male C57BL/6 mice
(20–25 g, Harlan, Indianapolis, IN, USA) were subjected to liver
IR injury as described previously.5 This method of partial hepatic
ischemia results in a segmental (B70%) hepatic ischemia but spares
the right lobe of the liver and prevents mesenteric venous congestion
by allowing portal decompression through the right and caudate
lobes of the liver. Sham-operated mice were subjected to laparotomy
and identical liver manipulations without the vascular occlusion.
Human APC or saline vehicle was injected intravenously (i.v.) before
reperfusion and then subcutaneously (s.c.) 2 h after reperfusion.
Three doses of APC were given to mice: 40, 100, or 250 mg/kg i.v.
prior to reperfusion and 80, 200 or 500 mg/kg s.c. 2 h after
reperfusion. Preliminary data showed that APC injection alone
in sham-operated mice had no effect on any of the injury para-
meters tested in the liver or in the kidney. Twenty-four hours
after reperfusion, the liver tissue subjected to IR and
kidney were collected to measure necrosis, neutrophil infiltration
(with immunohistochemistry), vascular permeability, apoptosis
(with terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling staining, DNA laddering and caspase 3 protein
cleavage), and F-actin integrity. In some mice, liver and kidney
were collected at 5 h and at 24 h after reperfusion to detect
inflammatory changes by RT-PCR for pro-inflammatory cytokine
mRNAs. We also collected plasma for the measurement of alanine
aminotransferase (ALT) and creatinine at 5 and 24 h after
reperfusion. Plasma levels of tumor necrosis factor (TNF)-a were
measured 24 h after reperfusion.
To test whether the blockade of PAR-1 would prevent the renal
and hepatic protective effects of APC after liver IR, we pretreated
mice with SCH 79797 (0.02–0.5mg/kg i.p.), a selective non-peptide
antagonist for PAR-1 30min before APC administration (250 mg/kg
i.v. before reperfusion and 500 mg/kg s.c. 2 h after reperfusion) in
mice subjected to liver IR.
Plasma ALT activity and creatinine level
The plasma and urine ALT activities were measured using the
Infinity ALT assay kit according to the manufacturer’s instructions
(Thermo Fisher Scientific, Waltham, MA, USA). Plasma creatinine
was measured by a colorimetric method based on the Jaffe
reaction.47
Histological analysis of hepatic and renal injury
For histological preparations, liver or kidney tissues were fixed in
10% formalin solution overnight. After automated dehydration
through a graded alcohol series, transverse liver slices were
embedded in paraffin, sectioned at 5 mm, and stained with
hematoxylin–eosin (H&E). To quantify the degree of hepatic
necrosis, H&E stains were digitally photographed and the percent
of necrotic area was quantified with NIH IMAGE (Image-J, 1.37v)
software by a person (SWC) who was blinded to the treatment each
animal had received. Twenty random sections were investigated per
slide to determine the percentage of necrotic area. Liver H&E
sections were also graded for IR injury by a pathologist (VDD)
blinded to the samples using the system devised by Suzuki et al.14 In
this classification, three liver injury indices are graded: sinusoidal
congestion (0–4), hepatocyte necrosis (0–4), and ballooning
degeneration (0–4) are graded for a total score of 0–12. No necrosis,
congestion, or centrilobular ballooning is given a score of 0 whereas
severe congestion/ballooning and 460% lobular necrosis is given a
value of four. Renal H&E sections were evaluated for renal cortical
vacuolization, proximal tubule simplification, and proximal tubule
hypereosinophilia by an experienced pathologist (VDD) who was
blinded to the treatment each animal had received.
Assessment of liver and kidney inflammation
Liver and kidney inflammation after hepatic ischemia was
determined with detection of neutrophil infiltration by immuno-
histochemistry (Serotec Clone 7/4 at 1:200 concentration for
primary and a biotin-conjugated secondary, rabbit anti-rat at
1:100 concentration) 24 h after hepatic IR as described previously48
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and by measuring mRNA-encoding markers of inflammation,
including keratinocyte-derived cytokine (KC), intercellular adhesion
molecule-1 (ICAM-1), monocyte chemoattractive protein-1
(MCP-1), macrophage inflammatory protein-2 (MIP-2), and TNF-
a 5 h after liver IR (Table 1). RT-PCR were performed as described.5
Vascular permeability of liver and kidney tissues
Changes in liver and kidney vascular permeability were assessed by
quantitating extravasation of Evans blue dye (EBD) into the tissue as
described by Awad et al.49 with some modifications. Briefly, 2% EBD
(Sigma Biosciences, St. Louis, MO, USA) was administered
intravenously at a dose of 20mg/kg 24 h after liver injury. One
hour later, mice were killed and perfused through the heart with PBS
and EDTAwith 10ml cold saline with heparin (100U/ml). Liver and
kidneys were then removed, allowed to dry overnight at 60 1C, and
the dry weights were determined. EBD was extracted in formamide
(20ml/g dry tissue; Sigma Biosciences), homogenized, and incu-
bated at 60 1C overnight. Homogenized samples were centrifuged at
12,000 g for 30min and the supernatants were measured at 620 and
740 nm in a spectrophotometer. The extravasated EBD concentra-
tion was calculated against a standard curve and the data expressed
as micrograms of EBD per gram of dry tissue weight.
Enzyme-linked immunosorbent assay for plasma TNF-a
Twenty-four hours after reperfusion, the plasma TNF-a level was
measured by the mouse TNF-a ELISA kit according to the
manufacturer’s instruction (eBiosciences, San Diego, CA, USA).
Detection of liver and kidney apoptosis
We used three independent assays to assess the degree of liver and
kidney apoptosis after IR: with in situ Terminal Deoxynucleotidyl
Transferase Biotin-dUTP Nick End-Labeling (TUNEL) assay,
detection of DNA laddering and immunoblotting for fragmented
caspase 3. For DNA laddering, liver and kidney tissues were removed
24 h after liver IR, apoptotic DNA fragments were extracted
according to the methods of Herrmann et al.50 and was electro-
phoresed at 70V in a 2.0% agarose gel in Tris-acetate–EDTA buffer.
This method of DNA extraction selectively isolates apoptotic,
fragmented DNA and leaves behind the intact chromatin. The gel
was stained with ethidium bromide and photographed under UV
illumination. DNA ladder markers (100 bp) were added to a lane of
each gel as a reference for the analysis of internucleosomal DNA
fragmentation. For the TUNEL assay, fixed liver, and kidney sections
obtained at 24 h after hepatic IR were deparaffinized in xylene and
rehydrated through graded ethanols to water. In situ TUNEL
staining was used for detecting DNA fragmentation in apoptosis
using a commercially available in situ cell death detection kit
(Roche, Nutley, NJ, USA) according to the manufacturer’s instruc-
tions. Caspase 3 immunoblotting was performed as described
previously.5
F-actin staining of liver and kidney sections
As breakdown of F-actin occurs early after IR, we visualized the
F-actin cytoskeleton by staining with phalloidin as an early index of
liver as well as renal injury.51 Twenty-four hours after hepatic IR,
liver and kidney tissues were embedded in Tissue-Tek oxytetracy-
cline compound (Fisher Scientific, Pittsburgh, PA, USA) and cut
into 5 mm sections. To reduce background staining, the sections were
incubated in 1% BSA dissolved in PBS for 10min at room
temperature. The sections were then stained with Alexafluor 594
(Red)-labeled phalloidin (Invitrogen, Carlsbad, CA, USA) for
30min at 37 1C in a humidified chamber in the dark. Sections were
then washed twice in PBS and mounted with Vectashield (Vector
Laboratories, Burlingame, CA, USA). F-actin images were visualized
with an Olympus IX81 epifluorescence microscope (Tokyo, Japan)
and captured and stored using SlideBook 4.2 software (Intelligent
Imaging Innovations Inc., Denver, CO, USA) on a personal
computer.
Protein determination
Protein contents were determined with a bicinchoninic acid protein
assay kit (Pierce Chemical Co., Rockford, IL, USA), using bovine
serum albumin as a standard.
Statistical analysis
All data are reported as mean±s.e. The overall significance of the
results was examined using one-way analysis of variance and the
significant differences between the groups were considered at a
Po0.05 with the appropriate Tukey’s post hoc test made for multiple
comparisons. Twenty-four hours survival rates between vehicle
hepatic IR and APC hepatic IR groups were compared with w2-test.
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Table 1 | RT-PCR primers used in this study
Genes Species Amplicon size (bp) Primer sequences (sense/antisense) Annealing 1C/cycle no.
GAPDH Mouse 450 50-ACCACAGTCCATGCCATCAC-30 65/15
50-CACCACCCTGTTGCTGTAGCC-30
TNF-a Mouse 290 50-TACTGAACTTCGGGGTGATTGGTCC-30 65/24
50-CAGCCTTGTCCCTTGAAGAGAACC-30
ICAM-1 Mouse 409 50-TGTTTCCTGCCTCTGAAGC-30 60/21
50-CTTCGTTTGTGATCCTCCG-30
KC Mouse 203 50-CAATGAGCTGCGCTGTCAGTG-30 60/26
50-CTTGGGGACACCTTTTAGCATC-30
MCP-1 Mouse 312 50-ACCTGCTGCTACTCATTCAC3-’ 60/22
50-TTGAGGTGGTTGTGGAAAAG3-’
MIP-2 Mouse 282 50-CCAAGGGTTGACTTCAAGAAC-30 60/25
50-AGCGAGGCACATCAGGTACG-30
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ICAM-1, intercellular adhesion molecule-1; KC, keratinocyte-derived chemokine, MCP-1, monocyte chemoattractant
protein 1, MIP-2, macrophage inflammatory protein 2, TNFa, tumor necrosis factor alpha.
Kidney International (2009) 76, 739–750 749
SW Park et al.: APC mediated liver and kidney protection o r ig ina l a r t i c l e
REFERENCES
1. Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia-reperfusion
injury. Am J Surg 2001; 181: 160–166.
2. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic ischemia/
reperfusion injury—a fresh look. Exp Mol Pathol 2003; 74: 86–93.
3. Behrends M, Hirose R, Park YH et al. Remote renal injury following partial
hepatic ischemia/reperfusion injury in rats. J Gastrointest Surg 2008; 12:
490–495.
4. Weinbroum AA, Hochhauser E, Rudick V et al. Direct induction of acute
lung and myocardial dysfunction by liver ischemia and reperfusion.
J Trauma 1997; 43: 627–633.
5. Lee HT, Park SW, Kim M et al. Acute kidney injury after hepatic ischemia
and reperfusion injury in mice. Lab Invest 2009; 89: 196–208.
6. Esmon CT. The protein C pathway. Chest 2003; 124: 26S–32S.
7. Mosnier LO, Griffin JH. Protein C anticoagulant activity in relation to anti-
inflammatory and anti-apoptotic activities. Front Biosci 2006; 11:
2381–2399.
8. Bartolome S, Wood JG, Casillan AJ et al. Activated protein C attenuates
microvascular injury during systemic hypoxia. Shock 2008; 29: 384–387.
9. Sharfuddin AA, Sandoval RM, Berg DT et al. Soluble thrombomodulin
protects ischemic kidneys. J Am Soc Nephrol 2009; 20: 524–534.
10. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of
recombinant human activated protein C for severe sepsis. N Engl J Med
2001; 344: 699–709.
11. Yesilirmak DC, Kumral A, Tugyan K et al. Effects of activated protein C on
neonatal hypoxic ischemic brain injury. Brain Res 2008; 1210: 56–62.
12. Pirat B, Muderrisoglu H, Ual MT et al. Recombinant human-activated
protein C inhibits cardiomyocyte apoptosis in a rat model of myocardial
ischemia-reperfusion. Coron Artery Dis 2007; 18: 61–66.
13. Teke Z, Sacar M, Yenisey C et al. Activated protein C attenuates intestinal
mucosal injury after mesenteric ischemia/reperfusion. J Surg Res 2008;
149: 219–230.
14. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ et al. Neutrophil infiltration as
an important factor in liver ischemia and reperfusion injury. Modulating
effects of FK506 and cyclosporine. Transplantation 1993; 55: 1265–1272.
15. Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA et al.
Factors in the pathophysiology of the liver ischemia-reperfusion injury.
J Surg Res 2008; 147: 153–159.
16. Biancofiore G, Davis CL. Renal dysfunction in the perioperative liver
transplant period. Curr Opin Organ Transplant 2008; 13: 291–297.
17. Ilmakunnas M, Pesonen EJ, Hockerstedt K et al. Graft protein C
entrapment is associated with reduced phagocyte activation during
reperfusion in human liver transplantation. Crit Care Med 2006; 34:
426–432.
18. Slofstra SH, ten CH, Spek CA. Signal transduction induced by activated
protein C: no role in protection against sepsis? Trends Mol Med 2006; 12:
374–381.
19. Vu TK, Hung DT, Wheaton VI et al. Molecular cloning of a functional
thrombin receptor reveals a novel proteolytic mechanism of receptor
activation. Cell 1991; 64: 1057–1068.
20. Dillon JP, Laing AJ, Cahill RA et al. Activated protein C attenuates acute
ischaemia reperfusion injury in skeletal muscle. J Orthop Res 2005; 23:
1454–1459.
21. Yoshikawa A, Kaido T, Seto S et al. Activated protein C prevents multiple
organ injury following extensive hepatectomy in cirrhotic rats. J Hepatol
2000; 33: 953–960.
22. Lehmann C, Meissner K, Knock A et al. Activated protein C improves
intestinal microcirculation in experimental endotoxaemia in the rat. Crit
Care 2006; 10: R157.
23. van Veen SQ, Levi M, van Vliet AK et al. Peritoneal lavage with activated
protein C alters compartmentalized coagulation and fibrinolysis and
improves survival in polymicrobial peritonitis. Crit Care Med 2006; 34:
2799–2805.
24. Strande JL, Hsu A, Su J et al. SCH 79797, a selective PAR1 antagonist,
limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res
Cardiol 2007; 102: 350–358.
25. Saikumar P, Dong Z, Weinberg JM et al. Mechanisms of cell death in
hypoxia/reoxygenation injury. Oncogene 1998; 17: 3341–3349.
26. Daemen MA, de Vries B, Buurman WA. Apoptosis and inflammation in
renal reperfusion injury. Transplantation 2002; 73: 1693–1700.
27. Lieberthal W, Koh JS, Levine JS. Necrosis and apoptosis in acute renal
failure. Semin Nephrol 1998; 18: 505–518.
28. Wadei HM, Mai ML, Ahsan N et al. Hepatorenal syndrome:
pathophysiology and management. Clin J Am Soc Nephrol 2006; 1:
1066–1079.
29. Schepke M. Hepatorenal syndrome: current diagnostic and therapeutic
concepts. Nephrol Dial Transplant 2007; 22(Suppl 8): viii2–viii4.
30. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease
associated with liver disorders: implications for liver transplantation.
Part I. Liver Transpl 2002; 8: 91–109.
31. Tanaka Y, Maher JM, Chen C et al. Hepatic ischemia-reperfusion induces
renal heme oxygenase-1 via NF-E2-related factor 2 in rats and mice. Mol
Pharmacol 2007; 71: 817–825.
32. Wanner GA, Ertel W, Muller P et al. Liver ischemia and reperfusion induces
a systemic inflammatory response through Kupffer cell activation. Shock
1996; 5: 34–40.
33. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb
Haemost 2007; 97: 738–747.
34. Furuichi K, Wada T, Iwata Y et al. CCR2 signaling contributes to ischemia-
reperfusion injury in kidney. J Am Soc Nephrol 2003; 14: 2503–2515.
35. Miura M, Fu X, Zhang QW et al. Neutralization of Gro alpha and
macrophage inflammatory protein-2 attenuates renal ischemia/
reperfusion injury. Am J Pathol 2001; 159: 2137–2145.
36. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine
expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;
110: 835–842.
37. Jaeschke H. Mechanisms of liver injury. II. Mechanisms of neutrophil-
induced liver cell injury during hepatic ischemia-reperfusion and other
acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol
2006; 290: G1083–G1088.
38. Okusa MD. The inflammatory cascade in acute ischemic renal failure.
Nephron 2002; 90: 133–138.
39. Klausner JM, Paterson IS, Goldman G et al. Postischemic renal injury is
mediated by neutrophils and leukotrienes. Am J Physiol 1989; 256:
F794–F802.
40. Benkoel L, Dodero F, Hardwigsen J et al. Effect of ischemia-reperfusion on
bile canalicular F-actin microfilaments in hepatocytes of human liver
allograft: image analysis by confocal laser scanning microscopy. Dig Dis
Sci 2001; 46: 1663–1667.
41. Kellerman PS, Norenberg SL, Jones GM. Early recovery of the actin
cytoskeleton during renal ischemic injury in vivo. Am J Kidney Dis 1996;
27: 709–714.
42. White SR, Williams P, Wojcik KR et al. Initiation of apoptosis by actin
cytoskeletal derangement in human airway epithelial cells. Am J Respir
Cell Mol Biol 2001; 24: 282–294.
43. Haley M, Cui X, Minneci PC et al. Recombinant human activated protein C
in sepsis: assessing its clinical use. Am J Med Sci 2004; 328: 215–219.
44. Wang Y, Thiyagarajan M, Chow N et al. Differential neuroprotection and
risk for bleeding from activated protein C with varying degrees of
anticoagulant activity. Stroke 2008; 40: 1864–1869.
45. Gale AJ, Sun X, Heeb MJ et al. Nonenzymatic anticoagulant activity of the
mutant serine protease Ser360Ala-activated protein C mediated by factor
Va. Protein Sci 1997; 6: 132–140.
46. Gupta A, Gerlitz B, Richardson MA et al. Distinct functions of activated
protein C differentially attenuate acute kidney injury. J Am Soc Nephrol
2009; 20: 267–277.
47. SLOT C. Plasma creatinine determination. A new and specific Jaffe
reaction method. Scand J Clin Lab Invest 1965; 17: 381–387.
48. Kim J, Kim M, Song JH et al. Endogenous A1 adenosine receptors protect
against hepatic ischemia reperfusion injury in mice. Liver Transpl 2008;
14: 845–854.
49. Awad AS, Ye H, Huang L et al. Selective sphingosine 1-phosphate 1
receptor activation reduces ischemia-reperfusion injury in mouse kidney.
Am J Physiol Renal Physiol 2006; 290: F1516–F1524.
50. Herrmann M, Lorenz HM, Voll R et al. A rapid and simple method for the
isolation of apoptotic DNA fragments. Nucleic Acids Res 1994; 22:
5506–5507.
51. Molitoris BA. Putting the actin cytoskeleton into perspective:
pathophysiology of ischemic alterations. Am J Physiol 1997; 272:
F430–F433.
750 Kidney International (2009) 76, 739–750
or ig ina l a r t i c l e SW Park et al.: APC mediated liver and kidney protection
